glp-1 cardiovascular benefits Variable weight-loss and were seen with drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear. https://www.medpagetoday.com/primarycare/obesity/122142 The Role of GLP-1RA Medications

Standard practice includes: Baseline thyroid function tests (TSH and free T4) before initiating GLP-1 therapy Repeat testing at 812 weeks after starting treatment or after dose escalation Regular monitoring every 36 months during active weight loss Return to annual monitoring once weight is stable and thyroid function remains consistent Adjustments to levothyroxine dosing may be necessary as weight changes

These medications work by mimicking the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways

They are designed to help fill in nutritional gaps and provide comprehensive support for your wellness goals

However, these findings are preliminary and hypothesis-generating rather than evidence of protective effects in humans